Cargando…

Tumor Antigenicity and a Pre-Existing Adaptive Immune Response in Advanced BRAF Mutant Colorectal Cancers

SIMPLE SUMMARY: BRAF mutant metastatic CRCs (BRAF-mCRCs) are considered a unique clinical entity characterized by a dismal prognosis and that do not respond efficiently to both standard chemotherapy and to orally selective inhibitors of BRAF(V600E). In this study, the gene expression profiles of 89...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bolzacchini, Elena, Libera, Laura, Church, Sarah E., Sahnane, Nora, Bombelli, Raffaella, Digiacomo, Nunzio, Giordano, Monica, Petracco, Guido, Sessa, Fausto, Capella, Carlo, Furlan, Daniela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405961/ https://www.ncbi.nlm.nih.gov/pubmed/36010943 http://dx.doi.org/10.3390/cancers14163951

Ejemplares similares

BRAF Mutation in Colorectal Rhabdoid and Poorly Differentiated Medullary Carcinomas
por: Bolzacchini, Elena, et al.
Publicado: (2019)

Correction to: Evaluation of global and intragenic hypomethylation in colorectal adenomas improves patient stratification and colorectal cancer risk prediction
por: Debernardi, Carla, et al.
Publicado: (2021)

Evaluation of global and intragenic hypomethylation in colorectal adenomas improves patient stratification and colorectal cancer risk prediction
por: Debernardi, Carla, et al.
Publicado: (2021)

Oxidative DNA damage induces hypomethylation in a compromised base excision repair colorectal tumourigenesis
por: Furlan, Daniela, et al.
Publicado: (2017)

MLH1 Promoter Methylation Could Be the Second Hit in Lynch Syndrome Carcinogenesis
por: Carnevali, Ileana Wanda, et al.
Publicado: (2023)

BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor
por: Sahnane, Nora, et al.
Publicado: (2020)

Aberrant DNA methylation profiles of inherited and sporadic colorectal cancer
por: Sahnane, Nora, et al.
Publicado: (2015)

Similarities and differences in gene expression profiles of BRCA1 methylated and mutated epithelial ovarian cancers
por: Sahnane, Nora, et al.
Publicado: (2023)

Methylation Drivers and Prognostic Implications in Sinonasal Poorly Differentiated Carcinomas
por: Libera, Laura, et al.
Publicado: (2021)

Acinar Cell Carcinoma of the Pancreas: Overview of Clinicopathologic Features and Insights into the Molecular Pathology
por: La Rosa, Stefano, et al.
Publicado: (2015)

BRAF-mutant hematopoietic malignancies
por: Abdel-Wahab, Omar, et al.
Publicado: (2014)

EBV(+) and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8(+) Intratumoral Lymphocytes
por: De Rosa, Simona, et al.
Publicado: (2018)

Case Report: Male Lobular Breast Cancer in Hereditary Cancer Syndromes
por: Carnevali, Ileana, et al.
Publicado: (2022)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
por: Di Stefano, Anna Luisa, et al.
Publicado: (2020)

Mixed Adenoneuroendocrine Carcinomas (MANECs) of the Gastrointestinal Tract: An Update
por: La Rosa, Stefano, et al.
Publicado: (2012)

Targeting mutant BRAF in colorectal cancer
por: Carroll, David, et al.
Publicado: (2013)

Optimizing the treatment of BRAF mutant melanoma
por: Settleman, Jeff
Publicado: (2014)

Dabrafenib for treatment of BRAF-mutant melanoma
por: Kainthla, Radhika, et al.
Publicado: (2013)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Molecular Features and Methylation Status in Early Onset (≤40 Years) Colorectal Cancer: A Population Based, Case-Control Study
por: Magnani, Giulia, et al.
Publicado: (2015)

Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors
por: Rossi, Sabrina, et al.
Publicado: (2016)

Variations of BRAF mutant allele percentage in melanomas
por: Hélias-Rodzewicz, Zofia, et al.
Publicado: (2015)

Novel combination therapies for BRAF-mutant melanoma
por: McArthur, Grant A
Publicado: (2015)

Agents to treat BRAF-mutant lung cancer
por: Alvarez, Jean G Bustamante, et al.
Publicado: (2019)

Current Advances in the Treatment of BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2020)

Mutant-selective degradation by BRAF-targeting PROTACs
por: Alabi, Shanique, et al.
Publicado: (2021)

Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma
por: Jain, Tania, et al.
Publicado: (2015)

BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells
por: Goulielmaki, Maria, et al.
Publicado: (2016)

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
por: Corcoran, Ryan B., et al.
Publicado: (2011)

Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment
por: Mak, Gabriel, et al.
Publicado: (2014)

Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF
por: Kim, Jae-Hyeon, et al.
Publicado: (2017)

BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study
por: Kaley, Thomas, et al.
Publicado: (2018)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
por: Hamid, Omid, et al.
Publicado: (2019)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2021)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

Mutant BRAF in low-grade epilepsy-associated tumors and focal cortical dysplasia
por: Marucci, Gianluca, et al.
Publicado: (2014)

Emerging treatment options for BRAF-mutant colorectal cancer
por: Ursem, Carling, et al.
Publicado: (2018)

Combination drug development in BRAF mutant colorectal cancer
por: Lam, Michael, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bdk0fpr3o1541utqal6ejd6s9t